Skip to contents

Michael O'Leary, MD
Senior Surgeon, Brigham and Women's Hospital
Professor of Surgery, Harvard Medical School

Brigham and Women's Hospital
Department of Surgery
Urology
75 Francis Street
Boston, MA 02115


Edit Profile


Research Narrative:

My major focus has been on the development and validation of hard measures of subjective outcomes in Urologic disease. This has resulted in six indices that are now widely used throughout the world, having been linguistically and culturally validated in over a dozen languages. These include:

  • The International Prostate Symptom Score (Journal of Urology 153 Volume 1:99-103,1995)
  • The Symptom Problem Index (Urology 49 Suppl 5A: 58-63,1997, the BPH Impact Index (MedCare 33 Volume 4:1450155,1995)
  • Brief Male Sexual Function Inventory (Urology 46 Volume 5:697-706,1995)
  • The National Institutes of Health Chronic Prostatitis Symptom Index (Journal of Urology 162(8): 369-375, 1999)
  • The Interstitial Cystitis Symptom and Problem Indices (Urology 49: Suppl 5A:58-63,1997), both of which have been funded by NIH R0-1 Grants.

I have also been an investigator in clinical trials for new modalities of therapy for erectile dysfunction, some of which are now standard treatment (NEJM 334 Volume 14: 873-877,1996).

My current research focus includes benign prostatic hyperplasia (BPH), interstitial cystitis (IC), chronic prostatitis, and prostate cancer.


Education:
University of California, San Francisco, School of Medicine/Stanford University School of Medicine, 1989, Fellowship
Massachusetts General Hospital, 1987, Urology Residency
New England Medical Center - Tufts School of Medicine, 1982, Urology Residency
George Washington University School of Medicine and Health Sciences, 1980, MD

Other Professional Activities:
Director of Men's Health Center, Brigham and Women's Hospital

Publications (Pulled from Harvard Catalyst Profiles):

1. Warner SG, Kim SI, Chaurasiya S, O'Leary MP, Lu J, Sivanandam V, Woo Y, Chen NG, Fong Y. A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression. Mol Ther Oncolytics. 2019 Jun 28; 13:82-92.

2. Raja AS, Pourjabbar S, Ip IK, Baugh CW, Sodickson AD, O'Leary M, Khorasani R. Impact of a Health Information Technology-Enabled Appropriate Use Criterion on Utilization of Emergency Department CT for Renal Colic. AJR Am J Roentgenol. 2019 Jan; 212(1):142-145.

3. Eng OS, Raoof M, O'Leary MP, Lew MW, Wakabayashi MT, Paz IB, Melstrom LG, Lee B. Hypothermia Is Associated with Surgical Site Infection in Cytoreductive Surgery with Hyperthermic Intra-Peritoneal Chemotherapy. Surg Infect (Larchmt). 2018 Aug/Sep; 19(6):618-621.

4. O'Leary MP, Choi AH, Kim SI, Chaurasiya S, Lu J, Park AK, Woo Y, Warner SG, Fong Y, Chen NG. Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose. J Transl Med. 2018 04 26; 16(1):110.

5. Choi AH, O'Leary MP, Lu J, Kim SI, Fong Y, Chen NG. Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer. Mol Ther Oncolytics. 2018 Jun 29; 9:22-29.

6. O'Leary MP, Warner SG, Kim SI, Chaurasiya S, Lu J, Choi AH, Park AK, Woo Y, Fong Y, Chen NG. A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection. Mol Ther Oncolytics. 2018 Jun 29; 9:13-21.

7. O'leary MP, Ayabe RI, Dauphine CE, Hari DM, Ozao-Choy JJ. Building a Single-Site Robotic Cholecystectomy Program in a Public Teaching Hospital: Is It Safe for Patients and Feasible for Residents to Participate? Am Surg. 2018 Feb 01; 84(2):188-191.

8. O'Leary MP, Goldner BS, Abboy S, Mercado PD, Plurad HY. A single visit multidisciplinary model for managing patients with mutations in moderate and high-risk genes in a community practice setting. Fam Cancer. 2018 01; 17(1):175-178.

9. Dumitra S, O'Leary M, Raoof M, Wakabayashi M, Dellinger TH, Han ES, Lee SJ, Lee B. The Comprehensive Complication Index: a New Measure of the Burden of Complications After Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2018 Mar; 25(3):688-693.

10. Eng OS, Dumitra S, O'Leary M, Raoof M, Wakabayashi M, Dellinger TH, Han ES, Lee SJ, Paz IB, Lee B. Association of Fluid Administration With Morbidity in Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy. JAMA Surg. 2017 Dec 01; 152(12):1156-1160.